Serum Institute Of India Meningitis Vaccine Said Better Than GSK's
This article was originally published in PharmAsia News
Executive Summary
The Serum Institute of India's meningitis vaccine outperformed a GlaxoSmithKline vaccine used in sub-Saharan Africa
|
The Serum Institute of India's meningitis vaccine outperformed a GlaxoSmithKline vaccine used in sub-Saharan Africa. Serum researchers said in a published study their MenAfriVac vaccine was 96% successful in a key group of children under two years of age, versus 64% in a group given GSK's Mencevax Acwy. The lead author of the study estimated the Serum vaccine against the sub-Saharan strain of meningitis could prevent about 150,000 deaths in Africa by 2020. (Click here for more) "Billionaire-Led Indian Drug Maker's Vaccine Beats Glaxo In Study" - Bloomberg (U.S.) (6/16/11) |